Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
EU WC
0
NDC API
0
VMF
0
FDF
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Finished Drug Prices
NA
1. 3-(1-diphenylmethylazetidin-3-yl)-5-isopropyl-2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate
2. Cs 905
3. Cs-905
1. 123524-52-7
2. 3-(1-benzhydrylazetidin-3-yl) 5-isopropyl 2-amino-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
3. Calblock
4. Azelnidipine [inn]
5. Cs-905
6. Cs 905
7. Pv23p19yug
8. Ncgc00167436-01
9. Ncgc00167436-02
10. Dsstox_cid_120
11. Dsstox_rid_75382
12. Dsstox_gsid_20120
13. 3,5-pyridinedicarboxylic Acid, 2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-, 3-[1-(diphenylmethyl)-3-azetidinyl] 5-(1-methylethyl) Ester
14. 3-o-(1-benzhydrylazetidin-3-yl) 5-o-propan-2-yl 2-amino-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
15. Cas-123524-52-7
16. Unii-pv23p19yug
17. Rs-9054
18. Ccris 8650
19. Calblock (tn)
20. Mfcd00865803
21. Azelnidipine [mi]
22. Azelnidipine [jan]
23. Azelnidipine (jp17/inn)
24. Schembl49021
25. Azelnidipine [mart.]
26. 2-amino-1,4-dihydro-6-methyl-4-(3 Nitrophenyl)-3,5-pyridinedicarboxylic Acid 3-[1-(diphenylmethyl)-3-azetidinyl] 5-(1-methylethyl) Ester
27. 3,5-pyridinedicarboxylic Acid, 2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-, 3-(1-(diphenylmethyl)-3-azetidinyl) 5-(1-methylethyl) Ester, (+-)-
28. Azelnidipine [who-dd]
29. Chembl1275868
30. Dtxsid3020120
31. Chebi:31247
32. Bcpp000357
33. Hms3651d18
34. Hms3885m05
35. Amy22122
36. Hy-b0023
37. Tox21_112440
38. S3053
39. Akos015841674
40. Tox21_112440_1
41. Ac-2151
42. Bcp9000370
43. Ccg-270140
44. Cs-0949
45. Db09230
46. Ks-1248
47. Pb24693
48. Azelnidipine, >=98% (hplc), Powder
49. 3,5-pyridinedicarboxylic Acid, 1,4-dihydro-2-amino-6-methyl-4-(3-nitrophenyl)-, 3-(1-(diphenylmethyl)-3-azetidinyl) 5-(1-methylethyl) Ester, (+-)-
50. 3,5-pyridinedicarboxylic Acid, 1,4-dihydro-2-amino-6-methyl-4-(3-nitrophenyl)-, 3-(1-(diphenylmethyl)-3-azetidinyl)-5-(1-methylethyl) Esster, (+-)-
51. 3-(1-(diphenylmethyl)-3-azetidinyl) 5-isopropyl (+-)-2-amino-1,4-dihydro-6-methyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate
52. 3-[1-(diphenylmethyl)azetidin-3-yl] 5-(1-methylethyl) 2-amino-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
53. Ft-0655294
54. Sw219236-1
55. D01145
56. Ab01565841_02
57. 524a527
58. A805113
59. Sr-01000944916
60. Q-200664
61. Q4832365
62. Sr-01000944916-1
63. (+/-)-2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic Acid 3-(1-diphenylmethylazetidin-3-yl) Ester 5-isopropyl Ester
64. 2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic Acid 3-(1-diphenylmethylazetidin-3-yl)ester 5-isopropyl Ester
65. 2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic Acid 3-[1-(diphenylmethyl)-3-azetidinyl] 5-isopropyl Ester
66. 3-(1-(diphenylmethyl)-3-azetidinyl) 5-isopropyl (+/-)-2-amino-1,4-dihydro-6-methyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate
67. 3-[1-(diphenylmethyl)-3-azetidinyl] 5-isopropyl 2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate
68. O3-(1-benzhydrylazetidin-3-yl) O5-isopropyl 2-amino-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate;azelnidipine
Molecular Weight | 582.6 g/mol |
---|---|
Molecular Formula | C33H34N4O6 |
XLogP3 | 6 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 10 |
Exact Mass | 582.24783482 g/mol |
Monoisotopic Mass | 582.24783482 g/mol |
Topological Polar Surface Area | 140 Ų |
Heavy Atom Count | 43 |
Formal Charge | 0 |
Complexity | 1080 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
For the treatment of hypertension.
Azelnidipine is a vasodilator that induces a gradual decrease in blood pressure in hypertensive patients. Unlike other members of its drug class, azelnidipine does not induce reflex tachycardia due to vasodilation. This is likely due to the fact that it elicits a gradual fall in blood pressure It also exhibits a prolonged hypotensive effect and has been shown to have a strong anti-arteriosclerotic action in vessels due to its high affinity for vascular tissue and antioxidative activity. Clinical studies have demonstrated that azelnidipine markedly reduced heart rate and proteinuria in hypertensive patients by inhibiting sympathetic nerve activity. Azelnidipine has also been confirmed to have cardio-protective, neuroprotective, and anti-atherosclerotic properties, and has also been found to prevent insulin resistance.
Absorption
Oral ingestion of azelnidipine demonstrates rapid and dose-dependent absorption.
Route of Elimination
In one study, following a single 4mg oral dose of 14C-labeled azelnidipine in humans, about 26% of the drug was thought to br excreted in the urine and 63% in the feces during the 1 week period post administration.
Volume of Distribution
In a Chinese study examining the pharmacokinetics of the drug, the volume of distribution was found to be 1749 +/- 964.
Like most members of its class, azelnidipine primarily undergoes first-pass hepatic metabolism. Azelnidipine is metabolized by hepatic cytochrome P450 (CYP) 3A4 and has no active metabolite product. It may interact with other drugs or compounds that are substrates for this enzyme. Azelnidipine is lipophilic and has a potent affinity for membranes of vascular smooth muscle cells.
16 28 hours.
Azelnidipine inhibits trans-membrane Ca2+ influx through the voltage-dependent channels of smooth muscles in vascular walls. Ca2+ channels are classified into various categories, including L-type, T-type, N-type, P/Q-type, and R-type Ca2+ channels. The L-type Ca2+ channels. Normally, calcium induces smooth muscle contraction, contributing to hypertension. When calcium channels are blocked, the vascular smooth muscle does not contract, resulting in relaxation of vascular smooth muscle walls and decreased blood pressure.
Global Sales Information
Market Place
ABOUT THIS PAGE
A Azelnidipine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Azelnidipine, including repackagers and relabelers. The FDA regulates Azelnidipine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Azelnidipine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Azelnidipine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Azelnidipine supplier is an individual or a company that provides Azelnidipine active pharmaceutical ingredient (API) or Azelnidipine finished formulations upon request. The Azelnidipine suppliers may include Azelnidipine API manufacturers, exporters, distributors and traders.
click here to find a list of Azelnidipine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Azelnidipine Drug Master File in Japan (Azelnidipine JDMF) empowers Azelnidipine API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Azelnidipine JDMF during the approval evaluation for pharmaceutical products. At the time of Azelnidipine JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Azelnidipine suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Azelnidipine Drug Master File in Korea (Azelnidipine KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Azelnidipine. The MFDS reviews the Azelnidipine KDMF as part of the drug registration process and uses the information provided in the Azelnidipine KDMF to evaluate the safety and efficacy of the drug.
After submitting a Azelnidipine KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Azelnidipine API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Azelnidipine suppliers with KDMF on PharmaCompass.
Azelnidipine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Azelnidipine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Azelnidipine GMP manufacturer or Azelnidipine GMP API supplier for your needs.
A Azelnidipine CoA (Certificate of Analysis) is a formal document that attests to Azelnidipine's compliance with Azelnidipine specifications and serves as a tool for batch-level quality control.
Azelnidipine CoA mostly includes findings from lab analyses of a specific batch. For each Azelnidipine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Azelnidipine may be tested according to a variety of international standards, such as European Pharmacopoeia (Azelnidipine EP), Azelnidipine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Azelnidipine USP).
LOOKING FOR A SUPPLIER?